Long-Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response With Risankizumab in Patients With Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

    April W. Armstrong, Laura K. Ferris, Kristina Callis Duffin, Jud C. Janak, Adam Šíma, Thomas Eckmann, Huzefa Photowala, Manish R. Patel, Vishvas Garg, Bruce Strober
    Studysummary Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →